In a head-to-head trial, tirzepatide demonstrated a superior mean reduction in body weight compared to semaglutide over 72 weeks in adult patients with obesity but without type 2 diabetes. Tirzepatide achieved significant weight reduction and improved waist circumference, cardiac risk factors, and gastrointestinal safety profile.
Tirzepatide Tops Semaglutide for Weight Loss
Conexiant
May 13, 2025
